Tag Archives: Canakinumab

[ad_1] Novartis' plan to expand the market for its anti-inflammatory drug canakinumab (Ilaris) with a cardiovascular indication have encountered a problem with the US Food and Drug Administration (FDA). Vas Narasimhan, chairman …

[ad_1] Canakinumab administered at variable doses every 3 months was associated with a significant reduction in the risk of gout attacks, without altering serum uric acid levels, according to new data from …